Skip to main content
  • Pipeline
    • Overview
      • Dovitinib
      • Stenoparib
      • Ixempra®
      • Additional Programs
    • Clinical Trials
  • Technology
    • The DRP® Method
    • Scientific Publications
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Investors
  • Contact
    • General Inquires
  • Careers
    • Join Allarity
Menu
  • Pipeline
    • Overview
      • Dovitinib
      • Stenoparib
      • Ixempra®
      • Additional Programs
    • Clinical Trials
  • Technology
    • The DRP® Method
    • Scientific Publications
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Investors
    • Overview
    • News
    • Stock Info
    • Financials
    • Governance
    • Resources
  • Contact
    • General Inquires
  • Careers
    • Join Allarity
  • Overview
    • News
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
      • Analyst Coverage
    • Financials
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor Email Alerts
      • Investor Contacts
    • Presentations
Site Search

Board of Directors

  • Overview
    • News
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
      • Analyst Coverage
    • Financials
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor Email Alerts
      • Investor Contacts
    • Presentations

Quick Links

  • SEC Filings

IR Contact

investorrelations@allarity.com

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Allarity Therapeutics, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Allarity Therapeutics to send you the requested Investor Email Alert updates.

* Required

*
Investor Alert Options
*





Unsubscribe

Email Alert Sign Up Confirmation

Pipeline
Overview
– Dovitinib
– Stenoparib
– Ixempra®
– Additional Programs
– Clinical Trials

Technology The DRP® Platform Scientific Publications

About Us
Overview
Leadership
Board of Directors
SAB
Partnering

Investors
Overview
News
Stock Info
Financials
Governance
Resources
Presentations

Newsroom
Top News
Media Contact

Contact
General Inquires

Careers
Join Allarity

Copyright © 2023 Allarity Therapeutics, Inc. All Rights Reserved.

Unless otherwise specified, all product and service name appearing in this internet site are trademark owned by or licensed to Allarity, its subsidiaries or affiliates. No use of any Allarity trademark, trade name, or trade dress in this site may be made without the prior written authorization of Allarity, except to identify the product or services of company.

Terms of Use 

Privacy Policy

Social Media Policy

Cookie Policy
Allarity Therapeutics Logo

United States:
United States:
24 School Street, 2nd Floor,
Boston, MA 02108
USA
Tel. +1 401-426-4664

Denmark:
Venlighedsvej 1
2970 Hoersholm
Denmark
Tel. +45 88 74 24 14
CVR: 34623562